149 related articles for article (PubMed ID: 27513518)
41. Superior anti-tumor efficacy of diisopropylamine dichloroacetate compared with dichloroacetate in a subcutaneous transplantation breast tumor model.
Su L; Zhang H; Yan C; Chen A; Meng G; Wei J; Yu D; Ding Y
Oncotarget; 2016 Oct; 7(40):65721-65731. PubMed ID: 27582548
[TBL] [Abstract][Full Text] [Related]
42. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.
Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH
Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540
[TBL] [Abstract][Full Text] [Related]
43. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
44. Increased antitumor activity of tumor-specific peptide modified thymopentin.
Lao X; Li B; Liu M; Chen J; Gao X; Zheng H
Biochimie; 2014 Dec; 107 Pt B():277-85. PubMed ID: 25236717
[TBL] [Abstract][Full Text] [Related]
45. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice.
Wang Y; Lam JB; Lam KS; Liu J; Lam MC; Hoo RL; Wu D; Cooper GJ; Xu A
Cancer Res; 2006 Dec; 66(23):11462-70. PubMed ID: 17145894
[TBL] [Abstract][Full Text] [Related]
46. sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment.
Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B
Sci Rep; 2017 Apr; 7(1):579. PubMed ID: 28373646
[TBL] [Abstract][Full Text] [Related]
47. 16-kDa fragment of pleiotrophin acts on endothelial and breast tumor cells and inhibits tumor development.
Ducès A; Karaky R; Martel-Renoir D; Mir L; Hamma-Kourbali Y; Biéche I; Opolon P; Delbé J; Courty J; Perricaudet M; Griscelli F
Mol Cancer Ther; 2008 Sep; 7(9):2817-27. PubMed ID: 18790762
[TBL] [Abstract][Full Text] [Related]
48. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
49. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
Hu C; Huang Y; Chen Y
Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
[TBL] [Abstract][Full Text] [Related]
50. Dual function of RGD-modified VEGI-192 for breast cancer treatment.
Wu J; Jiang Y; Yang W; He Z; Meng S; Zhang Q; Lin M; Zhang H; Li W; Yang Y; Jia Y; Qian L; Lu D; Cai W; Luo G; Wang Y; Zhu X; Li M
Bioconjug Chem; 2012 Apr; 23(4):796-804. PubMed ID: 22455451
[TBL] [Abstract][Full Text] [Related]
51. Adenovirus-mediated ING4/IL-24 double tumor suppressor gene co-transfer enhances antitumor activity in human breast cancer cells.
Zhao Y; Li Z; Sheng W; Miao J; Yang J
Oncol Rep; 2012 Oct; 28(4):1315-24. PubMed ID: 22842937
[TBL] [Abstract][Full Text] [Related]
52. Anticancer activities of an anthocyanin-rich extract from black rice against breast cancer cells in vitro and in vivo.
Hui C; Bin Y; Xiaoping Y; Long Y; Chunye C; Mantian M; Wenhua L
Nutr Cancer; 2010; 62(8):1128-36. PubMed ID: 21058201
[TBL] [Abstract][Full Text] [Related]
53. VP-128, a novel oestradiol-platinum(II) hybrid with selective anti-tumour activity towards hormone-dependent breast cancer cells in vivo.
Van Themsche C; Parent S; Leblanc V; Descôteaux C; Simard AM; Bérubé G; Asselin E
Endocr Relat Cancer; 2009 Dec; 16(4):1185-95. PubMed ID: 19661132
[TBL] [Abstract][Full Text] [Related]
54. Alpha-momorcharin (α-MMC) exerts effective anti-human breast tumor activities but has a narrow therapeutic window in vivo.
Cao D; Sun Y; Wang L; He Q; Zheng J; Deng F; Deng S; Chang S; Yu X; Li M; Meng Y; Jin J; Shen F
Fitoterapia; 2015 Jan; 100():139-49. PubMed ID: 25447153
[TBL] [Abstract][Full Text] [Related]
55. Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity.
Al Safarjalani ON; Rais R; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1449-55. PubMed ID: 22373605
[TBL] [Abstract][Full Text] [Related]
56. Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells.
Lee EJ; Oh SY; Sung MK
Food Chem Toxicol; 2012 Nov; 50(11):4136-43. PubMed ID: 22926442
[TBL] [Abstract][Full Text] [Related]
57. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1.
Hu M; Wang J; Chen P; Reilly RM
Bioconjug Chem; 2006; 17(5):1280-7. PubMed ID: 16984139
[TBL] [Abstract][Full Text] [Related]
58. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
59. Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy.
Hedrick E; Lee SO; Doddapaneni R; Singh M; Safe S
Endocr Relat Cancer; 2015 Oct; 22(5):831-40. PubMed ID: 26229035
[TBL] [Abstract][Full Text] [Related]
60. [Expression of ER alpha in chemically induced MDA-MB-435 cells and its responsiveness to endocrine].
Fan J; Lu JS; Yin WJ; Lei W; Wu FY; Wu J; Hou YF; Li DQ; Di GH; Shen ZZ; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):886-9. PubMed ID: 17533736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
